A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single Ascending Dose and Multiple Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Parenterally Administered VH4524184 in Healthy Adults

Summary

The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.

Eligibility

Age range

18–55 years

Sex

All

Healthy volunteers

Yes

Interventions

• Drug
  Oral VH4524184

  VH4524184 to be taken orally.

• Drug
  VH4524184 Formulation A SC

  VH4524184 LAI Formulation A administered subcutaneously.

• Drug
  Placebo Formulation A SC

  Placebo Formulation A administered subcutaneously.

• Drug
  rHuPH20

  rHuPH20 administered subcutaneously.

• Drug
  VH4524184 Formulation B SC

  VH4524184 LAI Formulation B administered subcutaneously.

• Drug
  Placebo Formulation B SC

  Placebo Formulation B administered subcutaneously.

• Drug
  VH4524184 Formulation A IM

Locations (3)